Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1923 1
1941 1
1943 1
1945 1
1946 2
1947 2
1948 2
1949 1
1951 1
1952 1
1956 1
1957 2
1958 1
1959 1
1960 2
1962 8
1963 9
1964 7
1965 6
1966 7
1967 5
1968 5
1969 6
1970 3
1971 9
1972 10
1973 11
1974 11
1975 9
1976 12
1977 14
1978 8
1979 6
1980 6
1981 3
1982 9
1983 12
1984 8
1985 4
1986 3
1987 3
1988 11
1989 3
1990 2
1991 5
1992 1
1993 2
1994 5
1995 2
1996 1
1997 4
1998 5
1999 4
2000 3
2001 10
2002 7
2003 8
2004 3
2005 3
2006 2
2007 6
2008 8
2009 3
2010 7
2011 6
2012 3
2013 7
2014 8
2015 8
2016 2
2017 1
2019 2
2020 5
2021 4
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Results by year

Filters applied: . Clear all
Page 1
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Robert C, et al. Among authors: humphrey r. N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639810 Free article. Clinical Trial.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, Gulley JL, Gupta S, Humphrey RW, LaVallee TM, Le DT, Hubbard-Lucey VM, Papadimitrakopoulou VA, Postow MA, Rubin EH, Sharon E, Taube JM, Topalian SL, Zappasodi R, Sznol M, Sullivan RJ. Kluger HM, et al. Among authors: humphrey rw. J Immunother Cancer. 2020 Mar;8(1):e000398. doi: 10.1136/jitc-2019-000398. J Immunother Cancer. 2020. PMID: 32238470 Free PMC article.
Cardiac rehabilitation in Europe.
Humphrey R, Guazzi M, Niebauer J. Humphrey R, et al. Prog Cardiovasc Dis. 2014 Mar-Apr;56(5):551-6. doi: 10.1016/j.pcad.2013.08.004. Epub 2013 Oct 5. Prog Cardiovasc Dis. 2014. PMID: 24607021 Review.
Improved endpoints for cancer immunotherapy trials.
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Hoos A, et al. Among authors: humphrey r. J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8. J Natl Cancer Inst. 2010. PMID: 20826737 Free PMC article. Review.
Tai chi in cardiac rehabilitation.
Humphrey R. Humphrey R. J Cardiopulm Rehabil. 2003 Mar-Apr;23(2):97-9. doi: 10.1097/00008483-200303000-00005. J Cardiopulm Rehabil. 2003. PMID: 12668930 No abstract available.
364 results